Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Sells 18,531 Shares

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 18,531 shares of the stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $3.52, for a total value of $65,229.12. Following the completion of the sale, the insider owned 52,274 shares of the company’s stock, valued at $184,004.48. This trade represents a 26.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.33, for a total value of $35,231.40.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total value of $31,667.22.
• On Thursday, July 2nd, Financial Lp Hrt acquired 7,851 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average price of $3.54 per share, with a total value of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average price of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Price Performance

SHPH traded down $0.29 during trading on Thursday, reaching $3.28. The company had a trading volume of 125,987 shares, compared to its average volume of 555,046. Shuttle Pharmaceuticals Holdings, Inc. has a 12 month low of $2.90 and a 12 month high of $55.90. The business’s fifty day moving average price is $5.30 and its 200 day moving average price is $10.27. The company has a market cap of $2.10 million, a P/E ratio of -0.07 and a beta of 0.29.

Institutional Trading of Shuttle Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals in the 4th quarter valued at about $26,000. Boothbay Fund Management LLC bought a new stake in shares of Shuttle Pharmaceuticals in the 4th quarter valued at about $37,000. Ikarian Capital LLC acquired a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at about $124,000. Finally, Connective Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals in the 3rd quarter valued at about $357,000. Institutional investors own 4.58% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on SHPH shares. Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Shuttle Pharmaceuticals has a consensus rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .